SCHEMBL13049746

SCHEMBL13049746

Cc1cc(-c2oc3ccccc3c2C=O)ccc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.42
▸ MEN1 O00255 2/20 0.40
▸ PTGS2 P35354 5/20 0.40
▸ KDM4E B2RXH2 2/20 0.38
▸ PTGS1 P23219 2/20 0.38
▸ THRB P10828 1/20 0.38
▸ RET P07949 2/20 0.38
▸ TP53 P04637 2/20 0.38
▸ ALOX12 P18054 2/20 0.38
▸ LMNA P02545 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ KDR P35968 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ ABCG2 Q9UNQ0 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ ST6GAL1 P15907 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13049740 0.81 L3MBTL1 (0.41) KMT2AMEN1PTGS2KDM4ERET
SCHEMBL28923425 0.80 RET (0.57) KMT2AMEN1PTGS2KDM4ETHRB
SCHEMBL30142360 0.80 RET (0.57) KMT2AMEN1PTGS2KDM4ETHRB
SCHEMBL1554147 0.76 DDR2 (0.57) KMT2AMEN1KDM4ETHRBRET
SCHEMBL13049757 0.76 KMT2A (0.39) KMT2AMEN1KDM4ERETTP53
SCHEMBL13049737 0.75 L3MBTL1 (0.55) L3MBTL1CYP2C19
SCHEMBL28209719 0.70 KDM4E (0.44) KMT2AMEN1PTGS2KDM4EPTGS1
SCHEMBL19401472 0.70 PTGS2 (0.33) PTGS2PTGS1MAPT
SCHEMBL13049744 0.70 ABCG2 (0.55) KMT2AMEN1KDM4ETHRBTP53
SCHEMBL2448418 0.69 KDM4E (0.51) KMT2AMEN1KDM4ETHRBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7837981-B2 Methods for imaging soluble A-beta GENERAL ELECTRIC COMPANY (US) 2010-11-23 — — US disclosed
US-7837981-B2 Methods for imaging soluble A-beta GENERAL ELECTRIC COMPANY (US) 2010-11-23 — — US disclosed
US-7727511-B2 Agents for imaging soluble a-beta GENERAL ELECTRIC COMPANY (US) 2010-06-01 — — US disclosed
US-7727511-B2 Agents for imaging soluble a-beta GENERAL ELECTRIC COMPANY (US) 2010-06-01 — — US disclosed
US-20070189967-A1 AGENTS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-08-16 — — US disclosed
US-20070189967-A1 AGENTS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-08-16 — — US disclosed
US-20070140960-A1 METHODS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-06-21 — — US disclosed
US-20070140960-A1 METHODS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070140960-A1 METHODS FOR IMAGING SOLUBLE A-BETA APBA1, APP, FABP7 KMT2A 4355/4885MEN1 1513/4885PTGS2 3067/4885
US-20070189967-A1 AGENTS FOR IMAGING SOLUBLE A-BETA APBA1, APP, FABP7 KMT2A 4536/4885MEN1 1254/4885PTGS2 2898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback